Disease · MONDO_0005045
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12 | 69 of 142 | 25 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24 | 70 of 142 | 5 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12 | 74 of 142 | 8 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24 | 83 of 142 | 34 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: deaths from any cause | 0 of 142 | 0 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: serious adverse events | 8 of 142 | 13 of 140 | 282 | NCT05186818 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: Proportion of Participants With at Least 1 Class Improvement in NYHA Functional Class From Baseline to Week 30 | 80 of 123 | 40 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: deaths from any cause | 0 of 123 | 1 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: Percentage of Participants Achieving A Clinical Response | 45 of 123 | 22 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: serious adverse events | 14 of 123 | 12 of 128 | 251 | NCT03470545 | Trial comparisons |
| Eleclazine 30/3/6 mg vs Placebo: deaths from any cause | 0 of 86 | 0 of 86 | 172 | NCT02291237 | Trial comparisons |
| Eleclazine 30/3/6 mg vs Placebo: serious adverse events | 14 of 86 | 16 of 86 | 172 | NCT02291237 | Trial comparisons |
| Mavacamten vs Placebo: deaths from any cause | 1 of 108 | 0 of 56 | 164 | NCT04349072 | Trial comparisons |
| Mavacamten vs Placebo: serious adverse events | 21 of 108 | 1 of 55 | 163 | NCT04349072 | Trial comparisons |
| Mavacamten vs Placebo to Mavacamten: Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16 | 35 of 56 | 12 of 56 | 112 | NCT04349072 | Trial comparisons |
| Mavacamten vs Placebo to Mavacamten: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 | 10 of 56 | 43 of 56 | 112 | NCT04349072 | Trial comparisons |
| Mavacamten vs Placebo: Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30. | 32 of 54 | 2 of 27 | 81 | NCT05174416 | Trial comparisons |
| Mavacamten vs Placebo: Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30 | 32 of 54 | 4 of 27 | 81 | NCT05174416 | Trial comparisons |
| Mavacamten vs Placebo: deaths from any cause | 0 of 54 | 0 of 27 | 81 | NCT05174416 | Trial comparisons |
| Mavacamten vs Placebo: Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30 | 26 of 54 | 1 of 27 | 81 | NCT05174416 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005045/comparisons